Enliven Therapeutics Inc. (ELVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enliven Therapeutics Inc. (ELVN) Competitors
The companies most similar to Enliven Therapeutics are Tango Therapeutics (TNGX), Viridian Therapeutics (VRDN) and Iovance Biotherapeutics (IOVA). By market cap, Enliven Therapeutics ranks 4th of the 13 companies on this page; Erasca (ERAS) is the largest at $5.50B.
Peer Comparison
ELVN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Enliven Therapeutics (ELVN) | $3.59B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tango Therapeutics Inc (TNGX) | $4.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Vericel Corp Ord (VCEL) | $2.91B | 89.8x | 9.1x | 10.3% | N/A | 26.5% | 0.00% |
| Erasca Inc (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Denali Therapeutics Inc (DNLI) | $3.00B | N/A | 159.3x | 0.0% | N/A | -100.0% | 0.00% |
| Palvella Therapeutics, Inc (PVLA) | $2.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Xenon Pharmaceuticals Inc (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Celcuity LLC (CELC) | $3.15B | N/A | N/A | 0.0% | -25.2% | 0.0% | 0.00% |
| Peer median | $3.27B | 178.2x | 9.1x | 0.0% | -21.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Enliven Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Tango Therapeutics Inc (TNGX) | Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation... | TNGX competitors |
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Vericel Corp Ord (VCEL) | Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures... | VCEL competitors |
| Erasca Inc (ERAS) | Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers... | ERAS competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Denali Therapeutics Inc (DNLI) | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. | DNLI competitors |
| Palvella Therapeutics, Inc (PVLA) | Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from... | PVLA competitors |
| Xenon Pharmaceuticals Inc (XENE) | Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders... | XENE competitors |
| Celcuity LLC (CELC) | Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. | CELC competitors |
Frequently Asked Questions About ELVN
Who are Enliven Therapeutics' main competitors?
The companies most similar to Enliven Therapeutics include Tango Therapeutics (TNGX), Viridian Therapeutics (VRDN), Iovance Biotherapeutics (IOVA), Legend Biotech (LEGN) and Xencor (XNCR), listed from the closest match.
Who is Enliven Therapeutics' biggest competitor?
Erasca (ERAS) is the largest of the similar companies at $5.50B; Tango Therapeutics (TNGX) is the closest match by business profile, size, sector and industry.
How does ELVN stock compare with its competitors?
ELVN's net margin is 0.0% against a peer median of 0.0%.
Which of Enliven Therapeutics' competitors pays a higher dividend?
Enliven Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Enliven Therapeutics bigger than its competitors?
No. Enliven Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Erasca (ERAS) at $5.50B.
ELVN pages: Overview, Earnings, Forecast, Financials, Competitors